The Efficacy of Anlotinib Plus Whole Brain Radiotherapy in Advanced Non-Small Cell Lung Cancer With Multiple Brain Metastases: A Retrospective Study.

IF 2.3 3区医学 Q3 ONCOLOGY

Thoracic Cancer Pub Date : 2025-01-01 Epub Date: 2024-12-05 DOI:10.1111/1759-7714.15498

Lipin Liu, Yonggang Xu, Hong Gao, Ting Zhao, Dazhi Chen, Jingyi Jin, Cui Gao, Gaofeng Li, Qiuzi Zhong

{"title":"The Efficacy of Anlotinib Plus Whole Brain Radiotherapy in Advanced Non-Small Cell Lung Cancer With Multiple Brain Metastases: A Retrospective Study.","authors":"Lipin Liu, Yonggang Xu, Hong Gao, Ting Zhao, Dazhi Chen, Jingyi Jin, Cui Gao, Gaofeng Li, Qiuzi Zhong","doi":"10.1111/1759-7714.15498","DOIUrl":null,"url":null,"abstract":"Purpose: This study aimed to compare the efficacy of anlotinib plus whole-brain radiotherapy (WBRT) with that of WBRT alone in non-small cell lung cancer (NSCLC) patients with multiple brain metastases (BMs).Methods: The clinical data of patients with NSCLC and multiple BMs who received WBRT between 2019 and 2022 were collected. The patients were assigned to anlotinib plus WBRT group and WBRT group according to the treatment used.Results: A total of 64 patients were eligible for analysis; 21 were treated with anlotinib plus WBRT, and 43 were treated with WBRT. The anlotinib plus WBRT group had a greater proportion of patients who were young and had a better performance status and adenocarcinoma histology than did the WBRT group. The median follow-up time was 18.0 months. The median intracranial progression-free survival (iPFS) was significantly longer in the anlotinib plus WBRT group than in the WBRT group (12.9 months vs. 7.4 months, p = 0.004). The median overall survival (OS) was 14.6 months in the anlotinib plus WBRT group and 9.4 months in the WBRT group (p = 0.039). Considering death as a competing risk to intracranial progression, the 1-year cumulative incidence of intracranial progression in the anlotinib plus WBRT group (26.7%) was significantly lower than that in the WBRT group (64.3%) (p = 0.021). There was no significant difference in treatment-related toxicity between the anlotinib plus WBRT group and the WBRT group.Conclusion: Compared with WBRT alone, anlotinib plus WBRT might confer superior intracranial PFS for NSCLC patients with multiple BMs without increasing treatment-related toxicity.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":" ","pages":"e15498"},"PeriodicalIF":2.3000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11729404/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thoracic Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/1759-7714.15498","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/5 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study aimed to compare the efficacy of anlotinib plus whole-brain radiotherapy (WBRT) with that of WBRT alone in non-small cell lung cancer (NSCLC) patients with multiple brain metastases (BMs).

Methods: The clinical data of patients with NSCLC and multiple BMs who received WBRT between 2019 and 2022 were collected. The patients were assigned to anlotinib plus WBRT group and WBRT group according to the treatment used.

Results: A total of 64 patients were eligible for analysis; 21 were treated with anlotinib plus WBRT, and 43 were treated with WBRT. The anlotinib plus WBRT group had a greater proportion of patients who were young and had a better performance status and adenocarcinoma histology than did the WBRT group. The median follow-up time was 18.0 months. The median intracranial progression-free survival (iPFS) was significantly longer in the anlotinib plus WBRT group than in the WBRT group (12.9 months vs. 7.4 months, p = 0.004). The median overall survival (OS) was 14.6 months in the anlotinib plus WBRT group and 9.4 months in the WBRT group (p = 0.039). Considering death as a competing risk to intracranial progression, the 1-year cumulative incidence of intracranial progression in the anlotinib plus WBRT group (26.7%) was significantly lower than that in the WBRT group (64.3%) (p = 0.021). There was no significant difference in treatment-related toxicity between the anlotinib plus WBRT group and the WBRT group.

Conclusion: Compared with WBRT alone, anlotinib plus WBRT might confer superior intracranial PFS for NSCLC patients with multiple BMs without increasing treatment-related toxicity.

查看原文本刊更多论文

安洛替尼加全脑放疗治疗晚期非小细胞肺癌合并多发性脑转移的疗效：回顾性研究。

目的：本研究旨在比较anlotinib联合全脑放疗（WBRT）与单独应用WBRT治疗非小细胞肺癌（NSCLC）多发脑转移（BMs）患者的疗效。方法：收集2019 - 2022年接受WBRT治疗的NSCLC合并多发性脑转移患者的临床资料。根据治疗方案将患者分为安洛替尼加WBRT组和WBRT组。结果：共有64例患者符合分析条件；安洛替尼联合WBRT治疗21例，WBRT治疗43例。与WBRT组相比，anlotinib + WBRT组有更大比例的年轻患者，具有更好的表现状态和腺癌组织学。中位随访时间为18.0个月。anlotinib + WBRT组的中位颅内无进展生存期（iPFS）明显长于WBRT组（12.9个月vs. 7.4个月，p = 0.004）。anlotinib + WBRT组的中位总生存期（OS）为14.6个月，WBRT组为9.4个月（p = 0.039）。考虑到死亡是颅内进展的竞争风险，anlotinib + WBRT组1年累积颅内进展发生率（26.7%）显著低于WBRT组（64.3%）（p = 0.021）。anlotinib + WBRT组与WBRT组在治疗相关毒性方面无显著差异。结论：与单用WBRT相比，anlotinib联合WBRT可能为多发性脑转移的NSCLC患者提供更好的颅内PFS，而不会增加治疗相关的毒性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Thoracic Cancer ONCOLOGY-RESPIRATORY SYSTEM

CiteScore

5.20

自引率

3.40%

发文量

439

审稿时长

2 months

期刊介绍： Thoracic Cancer aims to facilitate international collaboration and exchange of comprehensive and cutting-edge information on basic, translational, and applied clinical research in lung cancer, esophageal cancer, mediastinal cancer, breast cancer and other thoracic malignancies. Prevention, treatment and research relevant to Asia-Pacific is a focus area, but submissions from all regions are welcomed. The editors encourage contributions relevant to prevention, general thoracic surgery, medical oncology, radiology, radiation medicine, pathology, basic cancer research, as well as epidemiological and translational studies in thoracic cancer. Thoracic Cancer is the official publication of the Chinese Society of Lung Cancer, International Chinese Society of Thoracic Surgery and is endorsed by the Korean Association for the Study of Lung Cancer and the Hong Kong Cancer Therapy Society. The Journal publishes a range of article types including: Editorials, Invited Reviews, Mini Reviews, Original Articles, Clinical Guidelines, Technological Notes, Imaging in thoracic cancer, Meeting Reports, Case Reports, Letters to the Editor, Commentaries, and Brief Reports.